Context Therapeutics Inc (NASDAQ: CNTX)’s stock price has increased by 16.18 compared to its previous closing price of 1.36. However, the company has seen a 14.49% increase in its stock price over the last five trading sessions. Proactive Investors reported 2023-11-10 that Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, toward a first-in-human clinical study. The company said it remains on track to file an Investigational New Drug (IND) for CTIM-76 with the US Food and Drug Administration in the first quarter of 2024.
Is It Worth Investing in Context Therapeutics Inc (NASDAQ: CNTX) Right Now?
Additionally, the 36-month beta value for CNTX is 2.14. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNTX is 14.04M and currently, short sellers hold a 0.29% ratio of that float. The average trading volume of CNTX on May 02, 2024 was 57.03K shares.
CNTX’s Market Performance
CNTX stock saw an increase of 14.49% in the past week, with a monthly gain of 27.42% and a quarterly increase of 53.40%. The volatility ratio for the week is 6.20%, and the volatility levels for the last 30 days are 9.11% for Context Therapeutics Inc (CNTX). The simple moving average for the last 20 days is 14.77% for CNTX stock, with a simple moving average of 40.43% for the last 200 days.
CNTX Trading at 25.18% from the 50-Day Moving Average
After a stumble in the market that brought CNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.51% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 6.20%, as shares surge +20.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.43% upper at present.
During the last 5 trading sessions, CNTX rose by +11.68%, which changed the moving average for the period of 200-days by +21.83% in comparison to the 20-day moving average, which settled at $1.3898. In addition, Context Therapeutics Inc saw 39.82% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CNTX
The total capital return value is set at -2.11. Equity return is now at value -102.79, with -88.71 for asset returns.
Currently, EBITDA for the company is -25.06 million with net debt to EBITDA at 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.83.
Conclusion
In conclusion, Context Therapeutics Inc (CNTX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
